{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:36:59Z","timestamp":1792525019185,"version":"4.5.0"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T00:00:00Z","timestamp":1676505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In recent years, considerable progress has been made in the standard treatment for chronic lymphocytic leukaemia (CLL) due to the availability of new potent drugs. However, the majority of data on CLL were derived from Western populations, with limited studies and guidelines on the management of CLL from an Asian population perspective. This consensus guideline aims to understand treatment challenges and suggest appropriate management approaches for CLL in the Asian population and other countries with a similar socio-economic profile. The following recommendations are based on a consensus by experts and an extensive literature review and contribute towards uniform patient care in Asia.<\/jats:p>","DOI":"10.1007\/s10238-023-01007-2","type":"journal-article","created":{"date-parts":[[2023,2,16]],"date-time":"2023-02-16T09:02:51Z","timestamp":1676538171000},"page":"2895-2907","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Expert consensus on the management of chronic lymphocytic leukaemia in Asia"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8351-4722","authenticated-orcid":false,"given":"Eric","family":"Tse","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8156-6978","authenticated-orcid":false,"given":"Yok Lam","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7069-0997","authenticated-orcid":false,"given":"Yeow Tee","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4253-760X","authenticated-orcid":false,"given":"Ping Chong","family":"Bee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soo Chin","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priscilla","family":"Caguioa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huynh","family":"Nghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresita","family":"Dumagay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2223-5711","authenticated-orcid":false,"given":"Lalita","family":"Norasetthada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suporn","family":"Chuncharunee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9484-5669","authenticated-orcid":false,"given":"Vivek","family":"Radhakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9754-0182","authenticated-orcid":false,"given":"Bhausaheb","family":"Bagal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tubagus Djumhana","family":"Atmakusuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia Ayu","family":"Mulansari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,16]]},"reference":[{"key":"1007_CR1","unstructured":"Mayo Clinic. Chronic lymphocytic leukemia. 2021. https:\/\/www.mayoclinic.org\/diseases-conditions\/chronic-lymphocytic-leukemia\/symptoms-causes\/syc-20352428. Accessed May 30 2022"},{"key":"1007_CR2","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.bjhh.2016.07.004","volume":"38","author":"CA Rodrigues","year":"2016","unstructured":"Rodrigues CA, Gon\u00e7alves MV, Ikoma MRV, et al. Diagnosis and treatment of chronic lymphocytic leukemia: recommendations from the Brazilian Group of Chronic Lymphocytic Leukemia. Rev Bras Hematol Hemoter. 2016;38:346\u201357. https:\/\/doi.org\/10.1016\/j.bjhh.2016.07.004.","journal-title":"Rev Bras Hematol Hemoter"},{"key":"1007_CR3","unstructured":"American Society of Clinical Oncology (ASCO) Leukemia-Chronic Lymphocytic-CLL: Statistics. In: Cancer.Net. 2022. https:\/\/www.cancer.net\/cancer-types\/leukemia-chronic-lymphocytic-cll\/statistics. Accessed May 30 2022"},{"issue":"8","key":"1007_CR4","doi-asserted-by":"publisher","first-page":"e14258","DOI":"10.1111\/ijcp.14258","volume":"75","author":"B Ko","year":"2021","unstructured":"Ko B, Chen L, Huang H, Chen H-M, Hsiao F-Y. Epidemiology, treatment patterns and survival of chronic lymphocytic leukaemia\/small lymphocytic lymphoma (CLL\/SLL) in Taiwan, 2006\u20132015. Int J Clin Pract. 2021;75(8):e14258. https:\/\/doi.org\/10.1111\/ijcp.14258.","journal-title":"Int J Clin Pract"},{"key":"1007_CR5","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1200\/GO.20.00032","volume":"6","author":"V Tejaswi","year":"2020","unstructured":"Tejaswi V, Lad DP, Jindal N, et al. Chronic lymphocytic leukemia: Real-world data from India. JCO Global Oncol. 2020;6:866\u201372. https:\/\/doi.org\/10.1200\/GO.20.00032.","journal-title":"JCO Global Oncol"},{"issue":"6","key":"1007_CR6","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1158\/1055-9965.EPI-11-0038","volume":"20","author":"CA Clarke","year":"2011","unstructured":"Clarke CA, Glaser SL, Gomez SL, et al. Lymphoid malignancies in US Asians: incidence rate differences by birthplace and acculturation lymphoid malignancies in US Asians. Cancer Epidemiol Biomarkers Prev. 2011;20(6):1064\u201377. https:\/\/doi.org\/10.1158\/1055-9965.EPI-11-0038.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"1007_CR7","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360. https:\/\/doi.org\/10.1182\/blood-2017-09-806398.","journal-title":"Blood"},{"issue":"5","key":"1007_CR8","doi-asserted-by":"publisher","first-page":"e473","DOI":"10.1097\/HS9.0000000000000473","volume":"4","author":"A Quinquenel","year":"2020","unstructured":"Quinquenel A, Aurran-Schleinitz T, Clavert A, et al. Diagnosis and treatment of chronic lymphocytic leukemia: recommendations of the French CLL Study Group (FILO). HemaSphere. 2020;4(5):e473. https:\/\/doi.org\/10.1097\/HS9.0000000000000473.","journal-title":"HemaSphere"},{"key":"1007_CR9","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1002\/cyto.b.21595","volume":"94","author":"AC Rawstron","year":"2018","unstructured":"Rawstron AC, Kreuzer K-A, Soosapilla A, et al. Reproducible diagnosis of chronic lymphocytic leukemia by flow cytometry: an European Research Initiative on CLL (ERIC) and European Society for Clinical Cell Analysis (ESCCA) Harmonisation project. Cytometry B Clin Cytom. 2018;94:121\u20138. https:\/\/doi.org\/10.1002\/cyto.b.21595.","journal-title":"Cytometry B Clin Cytom"},{"issue":"6","key":"1007_CR10","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1182\/blood-2016-03-707786","volume":"128","author":"A D\u2019Avola","year":"2016","unstructured":"D\u2019Avola A, Drennan S, Tracy I, et al. Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. Blood. 2016;128(6):816\u201326. https:\/\/doi.org\/10.1182\/blood-2016-03-707786.","journal-title":"Blood"},{"key":"1007_CR11","doi-asserted-by":"publisher","first-page":"461","DOI":"10.3747\/co.25.4092","volume":"25","author":"C Owen","year":"2018","unstructured":"Owen C, Gerrie AS, Banerji V, et al. Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia. Curr Oncol. 2018;25:461\u201374. https:\/\/doi.org\/10.3747\/co.25.4092.","journal-title":"Curr Oncol"},{"key":"1007_CR12","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s40364-020-00222-3","volume":"8","author":"X Yun","year":"2020","unstructured":"Yun X, Zhang Y, Wang X. Recent progress of prognostic biomarkers and risk scoring systems in chronic lymphocytic leukemia. Biomark Res. 2020;8:40. https:\/\/doi.org\/10.1186\/s40364-020-00222-3.","journal-title":"Biomark Res"},{"key":"1007_CR13","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1111\/j.1365-2141.1986.tb02969.x","volume":"62","author":"E Montserrat","year":"1986","unstructured":"Montserrat E, Sanchez-Bisono J, Vi\u00f1olas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol. 1986;62:567\u201375. https:\/\/doi.org\/10.1111\/j.1365-2141.1986.tb02969.x.","journal-title":"Br J Haematol"},{"key":"1007_CR14","doi-asserted-by":"publisher","first-page":"439","DOI":"10.3109\/10428199609054782","volume":"22","author":"M Hallek","year":"1996","unstructured":"Hallek M, Wanders L, Ostwald M, et al. Serum \u03b22-microglobulin and serum thymidine kinase are independent predictors of progression-free survival in chronic lymphocytic leukemia and immunocytoma. Leuk Lymphoma. 1996;22:439\u201347.","journal-title":"Leuk Lymphoma"},{"key":"1007_CR15","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/sj.leu.2402780","volume":"17","author":"C Magnac","year":"2003","unstructured":"Magnac C, Porcher R, Davi F, et al. Predictive value of serum thymidine kinase level for Ig-V mutational status in B-CLL. Leukemia. 2003;17:133\u20137. https:\/\/doi.org\/10.1038\/sj.leu.2402780.","journal-title":"Leukemia"},{"key":"1007_CR16","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.3389\/fimmu.2018.00683","volume":"57","author":"G Pratt","year":"2016","unstructured":"Pratt G, Thomas P, Marden N, et al. Evaluation of serum markers in the LRF CLL4 trial: \u03b22-microglobulin but not serum free light chains, is an independent marker of overall survival. Leuk Lymphoma. 2016;57:2342\u201350. https:\/\/doi.org\/10.3389\/fimmu.2018.00683.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1007_CR17","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"TJ Hamblin","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig VH genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94(6):1848\u201354. https:\/\/doi.org\/10.1182\/blood.V94.6.1848.","journal-title":"Blood"},{"key":"1007_CR18","doi-asserted-by":"publisher","first-page":"035220","DOI":"10.1101\/cshperspect.a035220","volume":"11","author":"N Chiorazzi","year":"2021","unstructured":"Chiorazzi N, Chen S-S, Rai KR. Chronic lymphocytic leukemia. Cold Spring Harb Perspect Med. 2021;11:035220. https:\/\/doi.org\/10.1101\/cshperspect.a035220.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1007_CR19","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1002\/cncr.31738","volume":"125","author":"EK Seymour","year":"2019","unstructured":"Seymour EK, Ruterbusch JJ, Beebe-Dimmer JL, Schiffer CA. Real-world testing and treatment patterns in chronic lymphocytic leukemia: a SEER patterns of care analysis: SEER patterns of care in CLL. Cancer. 2019;125:135\u201343. https:\/\/doi.org\/10.1002\/cncr.31738.","journal-title":"Cancer"},{"key":"1007_CR20","doi-asserted-by":"publisher","first-page":"261","DOI":"10.31768\/2312-8852.2018.40(4):261-267","volume":"40","author":"K Tari","year":"2018","unstructured":"Tari K, Shamsi Z, Reza Ghafari H, Atashi A, Shahjahani M, Abroun S. The role of the genetic abnormalities, epigenetic and microRNA in the prognosis of chronic lymphocytic leukemia. Exp Onc. 2018;40:261\u20137.","journal-title":"Exp Onc"},{"key":"1007_CR21","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1002\/gcc.22294","volume":"55","author":"SJT Huang","year":"2016","unstructured":"Huang SJT, Gillan TL, Gerrie AS, et al. Influence of clone and deletion size on outcome in chronic lymphocytic leukemia patients with an isolated deletion 13q in a population-based analysis in British Columbia, Canada: DELETION 13q IN CLL. Genes Chromosomes Cancer. 2016;55:16\u201324. https:\/\/doi.org\/10.1002\/gcc.22294.","journal-title":"Genes Chromosomes Cancer"},{"key":"1007_CR22","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1016\/j.clml.2017.04.001","volume":"17","author":"J Goy","year":"2017","unstructured":"Goy J, Gillan TL, Bruyere H, et al. Chronic lymphocytic leukemia patients with deletion 11q have a short time to requirement of first-line therapy, but long overall survival: results of a population-based cohort in British Columbia. Canada Clin Lymphoma Myeloma Leuk. 2017;17:382\u20139. https:\/\/doi.org\/10.1016\/j.clml.2017.04.001.","journal-title":"Canada Clin Lymphoma Myeloma Leuk"},{"key":"1007_CR23","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1182\/blood-2018-09-873083","volume":"133","author":"P Baliakas","year":"2019","unstructured":"Baliakas P, Jeromin S, Iskas M, et al. Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations, and clinical impact. Blood. 2019;133:1205\u201316. https:\/\/doi.org\/10.1182\/blood-2018-09-873083.","journal-title":"Blood"},{"key":"1007_CR24","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1080\/10428194.2019.1576038","volume":"60","author":"M Jaro\u0161ov\u00e1","year":"2019","unstructured":"Jaro\u0161ov\u00e1 M, Plevov\u00e1 K, Kota\u0161kov\u00e1 J, Doubek M, Posp\u00ed\u0161ilov\u00e1 S. The importance of complex karyotype in prognostication and treatment of chronic lymphocytic leukemia (CLL): a comprehensive review of the literature. Leuk Lymphoma. 2019;60:2348\u201355. https:\/\/doi.org\/10.1080\/10428194.2019.1576038.","journal-title":"Leuk Lymphoma"},{"key":"1007_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s13045-016-0320-z","volume":"9","author":"GM Rigolin","year":"2016","unstructured":"Rigolin GM, Saccenti E, Bassi C, et al. Extensive next-generation sequencing analysis in chronic lymphocytic leukemia at diagnosis: clinical and biological correlations. J Hematol Oncol. 2016;9:88. https:\/\/doi.org\/10.1186\/s13045-016-0320-z.","journal-title":"J Hematol Oncol"},{"key":"1007_CR26","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nature15395","volume":"526","author":"DA Landau","year":"2015","unstructured":"Landau DA, Tausch E, Taylor-Weiner AN, et al. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015;526:525\u201330. https:\/\/doi.org\/10.1038\/nature15395.","journal-title":"Nature"},{"key":"1007_CR27","doi-asserted-by":"publisher","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","volume":"28","author":"T Zenz","year":"2010","unstructured":"Zenz T, Eichhorst B, Busch R, et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28:4473\u20139. https:\/\/doi.org\/10.1200\/JCO.2009.27.8762.","journal-title":"J Clin Oncol"},{"key":"1007_CR28","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/ajh.24493","volume":"91","author":"S Molica","year":"2016","unstructured":"Molica S, Shanafelt TD, Giannarelli D, et al. The chronic lymphocytic leukemia international prognostic index predicts time to first treatment in early CLL: independent validation in a prospective cohort of early stage patients: CLL-IPI in Early CLL. Am J Hematol. 2016;91:1090\u20135. https:\/\/doi.org\/10.1002\/ajh.24493.","journal-title":"Am J Hematol"},{"key":"1007_CR29","unstructured":"Morrison VA. Assessment of fitness, function, and quality of life essential in treatment of older patients with CLL. In: The ASCO Post. 2016. https:\/\/ascopost.com\/issues\/july-10-2016\/assessment-of-fitness-function-and-quality-of-life-essential-in-treatment-of-older-patients-with-cll\/ (2016). Accessed 30 May 2022"},{"key":"1007_CR30","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1002\/cncr.31931","volume":"125","author":"S Sharma","year":"2019","unstructured":"Sharma S, Rai KR. Chronic lymphocytic leukemia (CLL) treatment: so many choices, such great options. Cancer. 2019;125:1432\u201340. https:\/\/doi.org\/10.1002\/cncr.31931.","journal-title":"Cancer"},{"key":"1007_CR31","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.3390\/cancers13102468","volume":"13","author":"M Bewarder","year":"2021","unstructured":"Bewarder M, Stilgenbauer S, Thurner L, et al. Current treatment options in CLL. Cancers (Basels). 2021;13:2468. https:\/\/doi.org\/10.3390\/cancers13102468.","journal-title":"Cancers (Basels)"},{"key":"1007_CR32","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376:1164\u201374. https:\/\/doi.org\/10.1016\/S0140-6736(10)61381-5.","journal-title":"Lancet"},{"key":"1007_CR33","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1182\/blood-2015-06-651125","volume":"127","author":"K Fischer","year":"2016","unstructured":"Fischer K, Bahlo J, Fink AM, et al. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016;127:208\u201315. https:\/\/doi.org\/10.1182\/blood-2015-06-651125.","journal-title":"Blood"},{"key":"1007_CR34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"15","author":"M Sengar","year":"2020","unstructured":"Sengar M, Jain H, Rajendra A, Rengaraj K, Thorat J. Frontline therapy of chronic lymphocytic leukemia: changing treatment paradigm. Curr Hematol Malig Rep. 2020;15:168\u201376. https:\/\/doi.org\/10.1016\/S1470-2045(16)30051-1.","journal-title":"Curr Hematol Malig Rep"},{"key":"1007_CR35","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1182\/blood-2015-09-667675","volume":"127","author":"PA Thompson","year":"2016","unstructured":"Thompson PA, Tam CS, O\u2019Brien SM, et al. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia. Blood. 2016;127:303\u20139. https:\/\/doi.org\/10.1182\/blood-2015-09-667675.","journal-title":"Blood"},{"key":"1007_CR36","doi-asserted-by":"publisher","first-page":"TPS7582","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS7582","volume":"36","author":"VT Julia","year":"2018","unstructured":"Julia VT, Carsten N, Kater AP, et al. The GAIA (CLL13) trial: An international intergroup phase III study for frontline therapy in chronic lymphocytic leukemia (CLL). J Clin Oncol. 2018;36:TPS7582\u2013TPS7582.","journal-title":"J Clin Oncol"},{"key":"1007_CR37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1186\/s13063-017-2138-6","volume":"18","author":"L Collett","year":"2017","unstructured":"Collett L, Howard DR, Munir T, et al. Assessment of ibrutinib plus rituximab in front-line CLL (FLAIR trial): study protocol for a phase III randomised controlled trial. Trials. 2017;18:387.","journal-title":"Trials"},{"key":"1007_CR38","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/S1470-2045(16)30051-1","volume":"17","author":"B Eichhorst","year":"2016","unstructured":"Eichhorst B, Fink A-M, Bahlo J, et al. First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol. 2016;17:928\u201342. https:\/\/doi.org\/10.1016\/S1470-2045(16)30051-1.","journal-title":"Lancet Oncol"},{"key":"1007_CR39","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1056\/NEJM200012143432402","volume":"343","author":"KR Rai","year":"2000","unstructured":"Rai KR, Peterson BL, Appelbaum FR, et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med. 2000;343:1750\u20137. https:\/\/doi.org\/10.1056\/NEJM200012143432402.","journal-title":"N Engl J Med"},{"key":"1007_CR40","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa1313984","volume":"370","author":"V Goede","year":"2014","unstructured":"Goede V, Fischer K, Busch R, et al. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med. 2014;370:1101\u201310. https:\/\/doi.org\/10.1056\/NEJMoa1313984.","journal-title":"N Engl J Med"},{"key":"1007_CR41","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/s41571-018-0037-8","volume":"15","author":"JA Burger","year":"2018","unstructured":"Burger JA, O\u2019Brien S. Evolution of CLL treatment\u2014from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018;15:510\u201327. https:\/\/doi.org\/10.1038\/s41571-018-0037-8.","journal-title":"Nat Rev Clin Oncol"},{"key":"1007_CR42","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/S1470-2045(20)30443-5","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax\u2013rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107\u201320. https:\/\/doi.org\/10.1016\/S1470-2045(20)30443-5.","journal-title":"N Engl J Med"},{"key":"1007_CR43","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1016\/S1470-2045(20)30443-5","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(20)30443-5.","journal-title":"N Engl J Med"},{"key":"1007_CR44","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","volume":"21","author":"O Al-Sawaf","year":"2020","unstructured":"Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2020;21:1188\u2013200. https:\/\/doi.org\/10.1016\/S1470-2045(20)30443-5.","journal-title":"Lancet Oncol"},{"key":"1007_CR45","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","volume":"373","author":"JA Burger","year":"2015","unstructured":"Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373:2425\u201337. https:\/\/doi.org\/10.1056\/NEJMoa1509388.","journal-title":"N Engl J Med"},{"key":"1007_CR46","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/s41375-019-0602-x","volume":"34","author":"JA Burger","year":"2020","unstructured":"Burger JA, Barr PM, Robak T, et al. Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL\/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia. 2020;34:787\u201398. https:\/\/doi.org\/10.1038\/s41375-019-0602-x.","journal-title":"Leukemia"},{"key":"1007_CR47","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1002\/ajh.25638","volume":"94","author":"T Munir","year":"2019","unstructured":"Munir T, Brown JR, O\u2019Brien S, et al. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma. Am J Hematol. 2019;94:1353\u201363. https:\/\/doi.org\/10.1002\/ajh.25638.","journal-title":"Am J Hematol"},{"key":"1007_CR48","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","volume":"395","author":"JP Sharman","year":"2020","unstructured":"Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE-TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278\u201391. https:\/\/doi.org\/10.1016\/S0140-6736(20)30262-2.","journal-title":"Lancet"},{"key":"1007_CR49","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1200\/JCO.19.03355","volume":"38","author":"P Ghia","year":"2020","unstructured":"Ghia P, Pluta A, Wach M, et al. ASCEND: phase III, randomized trial of acalabrutinib versus idelalisib plus rituximab or bendamustine plus rituximab in relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol. 2020;38:2849\u201361. https:\/\/doi.org\/10.1200\/JCO.19.03355.","journal-title":"J Clin Oncol"},{"key":"1007_CR50","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/hon.2943","volume":"40","author":"TA Eyre","year":"2022","unstructured":"Eyre TA, Hori S, Munir T. Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management. Hematol Oncol. 2022;40:129\u201359. https:\/\/doi.org\/10.1002\/hon.2943.","journal-title":"Hematol Oncol"},{"key":"1007_CR51","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","volume":"380","author":"N Jain","year":"2019","unstructured":"Jain N, Keating M, Thompson P, et al. Ibrutinib and venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380:2095\u2013103. https:\/\/doi.org\/10.1056\/NEJMoa1900574.","journal-title":"N Engl J Med"},{"key":"1007_CR52","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.1200\/JCO.19.00894","volume":"37","author":"P Hillmen","year":"2019","unstructured":"Hillmen P, Rawstron AC, Brock K, et al. Ibrutinib plus venetoclax in relapsed\/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37:2722\u20139. https:\/\/doi.org\/10.1200\/JCO.19.00894.","journal-title":"J Clin Oncol"},{"key":"1007_CR53","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","volume":"32","author":"B Eichhorst","year":"2021","unstructured":"Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:23\u201333. https:\/\/doi.org\/10.1016\/j.annonc.2020.09.019.","journal-title":"Ann Oncol"},{"key":"1007_CR54","unstructured":"NCCN Guidelines for Patients Chronic Lymphocytic Leukemia 2021. Chronic Lymphocytic Leukemia. 2021. https:\/\/www.nccn.org\/patients\/guidelines\/content\/PDF\/cll-patient.pdf. Accessed 30 May 2022"},{"key":"1007_CR55","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.bbmt.2016.09.013","volume":"22","author":"MA Kharfan-Dabaja","year":"2016","unstructured":"Kharfan-Dabaja MA, Kumar A, Hamadani M, et al. Clinical practice recommendations for use of allogeneic hematopoietic cell transplantation in chronic lymphocytic leukemia on behalf of the guidelines committee of the american society for blood and marrow transplantation. Biol Blood Marrow Transpl. 2016;22:2117\u201325. https:\/\/doi.org\/10.1016\/j.bbmt.2016.09.013.","journal-title":"Biol Blood Marrow Transpl"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01007-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10238-023-01007-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-023-01007-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T17:15:35Z","timestamp":1696094135000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10238-023-01007-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,16]]},"references-count":55,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["1007"],"URL":"https:\/\/doi.org\/10.1007\/s10238-023-01007-2","relation":{},"ISSN":["1591-9528"],"issn-type":[{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,16]]},"assertion":[{"value":"4 November 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Eric Tse has received research support from MSD. Priscilla Caguioa has served on scientific advisory boards for Astra Zeneca, Novartis, MSD, Takeda, Otsuka, Johnson and Johnson, and has received research support from Astra Zeneca, Roche, MSD, Mylan, Celltrion, Apellis International, and MorphoSys AG. Teresita Dumagay was the Primary Investigator in the Acalabrutinib Trial sponsored by AstraZeneca and has received an honorarium for separate lectures from Astra Zeneca, Janssen Pharmaceuticals, and Novartis. Vivek Radhakrishna has received advisory fees (institutional) from Pfizer India and institutional grants and\/or non-financial support from Intas Pharmaceuticals, Natco Pharmaceuticals, Roche India, BMS, Cipla Pharmaceuticals, Emcure, AstraZeneca, and Dr. Reddy\u2019s Laboratories, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}